Wynden Pharmaceuticals

Wynden Pharmaceuticals is a biotechnology company based in San Diego, California, dedicated to the discovery and development of novel small molecule inhibitors for the treatment of cancer. The company's primary focus is on the DNA damage response (DDR) pathway, specifically targeting Ubiquitin Specific Peptidase 1 (USP1) to exploit synthetic lethality in tumors with specific genetic deficiencies, such as BRCA mutations. Wynden is led by an experienced management team with a proven track record in oncology drug discovery and successful exits. Their lead programs aim to address significant unmet needs in solid tumors, including ovarian and triple-negative breast cancers. The company leverages deep expertise in medicinal chemistry and cancer biology to advance its pipeline of precision medicines.